BRCA1 and cancer: Given there is no basis on which to reliably predict a milder phenotype of reduced cancer risks or later-onset diagnosis, evidence-based BRCA1 risk ranges were provided to both patients [12], alongside standard clinical care for BRCA1 carriers.